ALLISON PULLEN: Open Payments
NPI 1477915742 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,205 in 63 payments from 12 companies in 2025. Trend: 2023 $488 · 2024 $1,162 · 2025 $2,205
Food & beverage: $2,205
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 16 | $546 |
| Ipsen Biopharmaceuticals, Inc | 11 | $376 |
| Gilead Sciences, Inc. | 11 | $297 |
| Janssen Biotech, Inc. | 2 | $272 |
| Novo Nordisk Inc | 3 | $183 |
| Mallinckrodt Hospital Products Inc. | 5 | $159 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $135 |
| Janssen Scientific Affairs, LLC | 2 | $121 |
| Mirum Pharmaceuticals, Inc. | 2 | $45 |
| Lilly USA, LLC | 1 | $31 |
Products named: REZDIFFRA, TREMFYA, IQIRVO, Wegovy, TERLIVAZ, XIFAXAN, Livdelzi, Livmarli.
Industry payments across MD — which companies pay providers there.
